Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CFRX's Cash-to-Debt is ranked higher than
73% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CFRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CFRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: No Debt Max: No Debt
Current: No Debt
0.18
No Debt
Interest Coverage No Debt
CFRX's Interest Coverage is ranked higher than
66% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CFRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CFRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -3.15
WACC vs ROIC
6.39%
158.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -136.19
CFRX's ROE % is ranked lower than
55% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CFRX: -136.19 )
Ranked among companies with meaningful ROE % only.
CFRX' s ROE % Range Over the Past 10 Years
Min: -136.19  Med: -89.31 Max: -61.21
Current: -136.19
-136.19
-61.21
ROA % -68.79
CFRX's ROA % is ranked higher than
55% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CFRX: -68.79 )
Ranked among companies with meaningful ROA % only.
CFRX' s ROA % Range Over the Past 10 Years
Min: -206.39  Med: -111.85 Max: -35.34
Current: -68.79
-206.39
-35.34
ROC (Joel Greenblatt) % -2342.17
CFRX's ROC (Joel Greenblatt) % is ranked lower than
72% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CFRX: -2342.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CFRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2342.17  Med: -1012.22 Max: -579.02
Current: -2342.17
-2342.17
-579.02
3-Year EBITDA Growth Rate 36.20
CFRX's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CFRX: 36.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CFRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 33.6 Max: 36.2
Current: 36.2
0
36.2
3-Year EPS without NRI Growth Rate 58.30
CFRX's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CFRX: 58.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CFRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 41.5 Max: 58.3
Current: 58.3
0
58.3
GuruFocus has detected 2 Warning Signs with ContraFect Corp CFRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CFRX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CFRX Guru Trades in

Q3 2017

CFRX Guru Trades in Q3 2017

Jim Simons 75,800 sh (New)
» More
Q4 2017

CFRX Guru Trades in Q4 2017

Jim Simons 194,500 sh (+156.60%)
» More
Q1 2018

CFRX Guru Trades in Q1 2018

Jim Simons 142,600 sh (-26.68%)
» More
» Details

Insider Trades

Latest Guru Trades with CFRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:RASP, TSE:7776, OTCPK:ARPO, LSE:TRX, XKRX:043090, NAS:CDMO, NAS:EVFM, NAS:COCP, XCNQ:THC, XKRX:041910, NAS:MDWD, NAS:ACER, OTCPK:CNBX, NAS:FWP, TSE:2370, XPAR:ADVIC, NAS:VTVT, AMEX:PFNX, XKRX:067370, NAS:ORGS » details
Traded in other countries:22R.Germany,
Headquarter Location:USA
ContraFect Corp is a biotechnology company engaged in the development of protein and antibody therapeutic products for life-threatening infectious diseases. The Company's product candidates are CF-301, CF-404.

ContraFect Corp is a US-based clinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through the single segment being Developing therapeutic protein and antibody products.

Ratios

vs
industry
vs
history
PB Ratio 14.17
CFRX's PB Ratio is ranked higher than
52% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CFRX: 14.17 )
Ranked among companies with meaningful PB Ratio only.
CFRX' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 16.88
Current: 14.17
0
16.88
EV-to-EBIT -5.06
CFRX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CFRX: -5.06 )
Ranked among companies with meaningful EV-to-EBIT only.
CFRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.26  Med: 0 Max: 0
Current: -5.06
-6.26
0
EV-to-EBITDA -5.09
CFRX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CFRX: -5.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
CFRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.32  Med: 0 Max: 0
Current: -5.09
-6.32
0
Current Ratio 10.62
CFRX's Current Ratio is ranked higher than
93% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CFRX: 10.62 )
Ranked among companies with meaningful Current Ratio only.
CFRX' s Current Ratio Range Over the Past 10 Years
Min: 0.18  Med: 6.91 Max: 18.37
Current: 10.62
0.18
18.37
Quick Ratio 10.62
CFRX's Quick Ratio is ranked higher than
93% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CFRX: 10.62 )
Ranked among companies with meaningful Quick Ratio only.
CFRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.18  Med: 6.91 Max: 18.37
Current: 10.62
0.18
18.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.90
CFRX's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CFRX: -53.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CFRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -95.6  Med: -53.9 Max: 0
Current: -53.9
-95.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 20.08
CFRX's Price-to-Net-Cash is ranked higher than
71% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. CFRX: 20.08 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CFRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.33  Med: 4.66 Max: 22.67
Current: 20.08
2.33
22.67
Price-to-Net-Current-Asset-Value 16.07
CFRX's Price-to-Net-Current-Asset-Value is ranked higher than
69% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CFRX: 16.07 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CFRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.28  Med: 4.42 Max: 18.13
Current: 16.07
2.28
18.13
Price-to-Tangible-Book 14.18
CFRX's Price-to-Tangible-Book is ranked higher than
59% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CFRX: 14.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CFRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.18  Med: 4.09 Max: 16
Current: 14.18
2.18
16
Earnings Yield (Greenblatt) % -19.73
CFRX's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CFRX: -19.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CFRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -485.54  Med: 0 Max: 0
Current: -19.73
-485.54
0

More Statistics

EPS (TTM) $ -0.41
Beta0.59
Volatility58.84%
52-Week Range $0.80 - 2.93
Shares Outstanding (Mil)73.66

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.91 -0.94 -1.00
EPS without NRI ($) -0.91 -0.94 -1.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}